https://www.selleckchem.com/pr....oducts/evobrutinib.h
Shunt occlusion prior to lenvatinib administration prevented hyperammonemia and hepatic encephalopathy. Shunt occlusion may be an effective treatment option to administer molecular target agents in patients with portosystemic shunts.Arteriovenous malformation (AVM) is defined as a disease that causes blood flow abnormality due to anastomoses of the arteries and veins. AVM can occur in any gastrointestinal tract, but pancreatic AVM (P-AVM) is very rare. Previous reports demonstrated that contrast-enhanced CT (CECT) typically showed a